Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

It was the view at the Sheffield Children's' Hospital that cryoprecipitate was a safer blood product than factor concentrate.

  • Read more about It was the view at the Sheffield Children's' Hospital that cryoprecipitate was a safer blood product than factor concentrate.

Dr Lilleyman preferred to use cryoprecipitate for the treatment of children as it only exposed patients to a very small number of UK donors and therefore reduced the risk of viral transmission.

  • Read more about Dr Lilleyman preferred to use cryoprecipitate for the treatment of children as it only exposed patients to a very small number of UK donors and therefore reduced the risk of viral transmission.

There were close links between the adult and paediatric treatment in Sheffield Children's Hospital, as well as a close relationship with the regional blood transfusion centre in Sheffield.

  • Read more about There were close links between the adult and paediatric treatment in Sheffield Children's Hospital, as well as a close relationship with the regional blood transfusion centre in Sheffield.

Dr Geoffrey Scott wrote to a patient and his wife about another patient attending the Bristol Haemophilia Centre who recently died of AIDS and described the risk of contracting the disease by using imported blood products as extremely small.

  • Read more about Dr Geoffrey Scott wrote to a patient and his wife about another patient attending the Bristol Haemophilia Centre who recently died of AIDS and described the risk of contracting the disease by using imported blood products as extremely small.

In her written statement to the Inquiry, Dr Helena Daly stated that the Bristol Royal Infirmary instituted home therapy for children with severe haemophilia from the age of about four. Cryoprecipitate was seen as impractical for home therapy.

  • Read more about In her written statement to the Inquiry, Dr Helena Daly stated that the Bristol Royal Infirmary instituted home therapy for children with severe haemophilia from the age of about four. Cryoprecipitate was seen as impractical for home therapy.

Dr Geoffrey Scott complained to Dr Geoffrey Tovey about the insolubility of the Elstree Factor 8 concentrate which meant it could no longer be used for home treatment and therefore more commercial Factor VIII would need to be purchased.

  • Read more about Dr Geoffrey Scott complained to Dr Geoffrey Tovey about the insolubility of the Elstree Factor 8 concentrate which meant it could no longer be used for home treatment and therefore more commercial Factor VIII would need to be purchased.

Dr Geoffrey Tovey published a statement regarding the introduction of heat-treated concentrates into the Bristol Haemophilia Centre. His policy was to use NHS products in preference to commercial products and where there was a shortfall of NHS products, priority was given to children and adults known to be hepatitis and HIV negative.

  • Read more about Dr Geoffrey Tovey published a statement regarding the introduction of heat-treated concentrates into the Bristol Haemophilia Centre. His policy was to use NHS products in preference to commercial products and where there was a shortfall of NHS products, priority was given to children and adults known to be hepatitis and HIV negative.

Professor Ian Hann stated that 21 children at the RHSC were infected with HIV relatively early in the HIV crisis, "probably as a result of the widespread use of commercial product."

  • Read more about Professor Ian Hann stated that 21 children at the RHSC were infected with HIV relatively early in the HIV crisis, "probably as a result of the widespread use of commercial product."

Dr Willoughby did not realise that commercial Factor VIII concentrates were exposing patients to the risk of viral infections until around 1983.

  • Read more about Dr Willoughby did not realise that commercial Factor VIII concentrates were exposing patients to the risk of viral infections until around 1983.

RHSC annual return showed 5,460 units of commercial concentrate was used for haemophilia treatment.

  • Read more about RHSC annual return showed 5,460 units of commercial concentrate was used for haemophilia treatment.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Current page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.